RenovoRx (RNXT) Total Non-Current Liabilities (2020)
RenovoRx (RNXT) posted Total Non-Current Liabilities of $3.3 million for Q4 2020.
RenovoRx (RNXT) Total Non-Current Liabilities (2020) Analysis & Trends
RenovoRx has reported Total Non-Current Liabilities for 1 years, with the latest figure at $3.3 million in Q4 2020.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $3.3 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $3.3 million (changed N/A YoY) and the FY2020 annual result came in at $3.3 million, changed N/A from the prior year.
- Total Non-Current Liabilities steadied at $3.3 million in Q4 2020 per RNXT's latest filing.
- Over five years, Total Non-Current Liabilities peaked at $3.3 million in Q4 2020 and troughed at $3.3 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 9.32 Bn |
| 10 | RenovoRx | 61.70 Mn | 61.70 Mn | 766,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 3.26 Mn |